Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

280.01 -13.99 (-4.76%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
47 48 Next >
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
These names are benefitting from M&A, clinical data and promising regulatory actions. 
Via Investor's Business Daily
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Amgen Touts Positive Data From Soliris-Based Biosimilar For Rare Blood Disorder
Via Benzinga
Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million
The biopharma buying spree continued Tuesday with glaucoma drugs maker Aerie. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Amgen's Return on Invested Capital Overview
  
Via Benzinga
Analyst Ratings for Amgen
Analysts have provided the following ratings for Amgen (NASDAQ:AMGN) within the last quarter: 
Via Benzinga
CNBC's Final Trades: Easterly Government Properties, ExxonMobil, Illinois Tool Works And This Health Care Company
On CNBC’s “Halftime Report Final Trades,” Jenny Harrington of Gilman Hill Asset Management said Easterly Government Properties Inc (NYSE: DEA) offers a 5.6% yield. 
Via Benzinga
Apple, IBM Are CNBC 'Fast Money' Calls Of The Day
CNBC’s "Fast Money: Halftime Report" delivers market-moving news to investors. 
Via Benzinga
Amgen Moves to Dismiss Regeneron's Antitrust Case Regarding Cholesterol Drug
Via Benzinga
75 Firms Going Ex-Dividend Next Week, Including Target, Amgen And Chevron
Ex-dividend dates are important to dividend investors because one must own a stock prior to its ex-dividend date in order to be eligible to receive its next dividend. 
Via Talk Markets
$100 Invested In Amgen 15 Years Ago Would Be Worth This Much Today
  Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 3.82% on an annualized basis producing an average annual return of 11.31%. Currently, Amgen has a market capitalization of... 
Via Benzinga
Amgen Q2 Earnings and Revenues Beat Estimates
Amgen came out with quarterly earnings of $4.65 per share. 
Via Talk Markets
Senate Finance Committee Expands Amgen's Tax Probe: Report
Senator Ron Wyden sent a letter to Amgen Inc (NASDAQ: AMGN) asking what methods the company has used to pay an average effective tax rate of around 12% over the past four years.  
Via Benzinga
3 Best Funds for Aggressive Investors
These are the three best funds for aggressive investors. ETFs like BUG, RYT, and BBH can make great investments in the rest of the year. 
Via InvestorPlace
4 Index Funds to Buy and Hold Forever
These are the best index funds to buy and hold in August. DIA, ONEQ, RYF and XSD can make great long-term investments. 
Via InvestorPlace
This Is What Whales Are Betting On Amgen
  A whale with a lot of money to spend has taken a noticeably bullish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 10 strange trades. 
Via Benzinga
Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock
Mizuho boosted the price target for Karuna Therapeutics, Inc. (NASDAQ: KRTX) from $190 to $276. Karuna Therapeutics shares fell 1.3% to $238.00 in pre-market trading. 
Via Benzinga
Amgen's Lumakras/Keytruda/Tecentriq Combo Data Flags Safety Concern
Via Benzinga
Two Appealing Biotech Stocks for Two Distinct investors
Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Small Cap Biotechs Perk Up On Dealmaking
With M&A picking up we would think smaller deals make sense for large cap biopharma to expand pipelines and complement technology. 
Via Talk Markets
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
The Nasdaq and small caps rose while the S&P 500 is hitting resistance. 
Via Investor's Business Daily
Amgen's Q2 Sales Impacted By Lower Prices, Currency Headwind, Reaffirms FY22 Outlook
Via Benzinga
What Are Whales Doing With Amgen
Someone with a lot of money to spend has taken a bearish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the big position showed up on publicly available... 
Via Benzinga
Amgen Narrows Sales Outlook Following Plans To Acquire ChemoCentryx
The company also reported a second-quarter beat and reiterated its earnings outlook. 
Via Investor's Business Daily
Recap: Amgen Q2 Earnings
Amgen (NASDAQ:AMGN) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:02 PM. Here's what investors need to know about the announcement. Earnings Amgen beat estimated earnings by 5.68%,... 
Via Benzinga
ChemoCentryx Shares Are Jumping 110% Thursday: Here's Why
Shares of ChemoCentryx, Inc. (NASDAQ: CCXI) are skyrocketing Thursday following a groundbreaking announcement for the biopharmaceutical company. Why Is It Moving? 
Via Benzinga
ChemoCentryx (NASDAQ: CCXI) to be Acquired by Amgen (NASDAQ: AMGN) for $3.7 Billion in Cash
ChemoCentryx, Inc. (NASDAQ: CCXI) is engaged as a biopharmaceutical company that is focused on the research, development and commercialization of 
Via Spotlight Growth
ChemoCentryx (CCXI) Stock Soars 100% on Amgen Acquisition
ChemoCentryx (CCXI) stock is rocketing higher on Thursday as investors react to news of an acquisition deal with Amgen (AMGN). 
Via InvestorPlace
Amgen Plans $3.7 Billion ChemoCentryx Buyout, Tapping Into A New Market
The company will pay $52 per share to buy ChemoCentryx, a rare disease-focused firm. 
Via Investor's Business Daily
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.